Vascular Dementia Market Expected to Grow at 4.5% Through 2036

The competitive environment is expected to evolve as investigational therapies progress through clinical development. Resverlogix, Charsire Biotechnology, ProNeurogen, Bausch Health, Hemostemix, and SciNeuro Pharmaceuticals are among the companies contributing to the emerging treatment landscape.

Apabetalone could represent an important development because of its selective targeting of BET proteins and its ability to influence multiple biological pathways through transcriptional and epigenetic mechanisms.

BAC is being investigated as an anti-inflammatory strategy, while PNA1 represents a neurovascular approach centered on MAS receptor signaling. Rifaximin SSD introduces another potentially differentiated strategy through the modulation of gut microbiota and systemic inflammatory processes.

If these candidates demonstrate meaningful clinical benefits and secure regulatory approvals, they could introduce new treatment options and potentially alter the competitive dynamics of the vascular dementia market over the coming years.

Vascular Dementia Epidemiology Outlook

Epidemiological trends remain a significant factor shaping future market potential. In 2025, the United States recorded the highest number of diagnosed prevalent vascular dementia cases across the 7MM, with approximately 1 million cases.

DelveInsight's analysis evaluates the disease burden and patient population from 2022 to 2036. The assessment includes total prevalent dementia cases, diagnosed prevalent dementia cases, diagnosed prevalent vascular dementia cases, age-specific and etiology-specific diagnosed prevalent cases, and treated vascular dementia cases.

The combination of population aging, cerebrovascular disease, cardiovascular risk factors, and improved diagnosis is expected to sustain demand for better disease management and innovative therapeutic solutions.

Get comprehensive vascular dementia forecasts, epidemiology, and pipeline intelligence. https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Future Outlook for the Vascular Dementia Market

The vascular dementia treatment landscape is entering a period of gradual transformation as researchers increasingly explore disease mechanisms beyond conventional symptomatic management. Emerging therapies targeting inflammation, neurovascular pathways, epigenetic regulation, and cardiometabolic mechanisms could help address some of the major limitations of current care.

According to DelveInsight's forecasting analysis, Apabetalone is anticipated to experience moderate uptake following a potential launch in 2032. Its peak market share is projected to vary across individual markets, reaching approximately 14% at its highest point, with adoption expected to stabilize over several years.